Diskusjon Triggere Porteføljer Aksjonærlister

Episurf Medical (EPIS-B)

The shareholders of Episurf Medical AB (publ) (Episurf or the Company) gathered in Stockholm, Sweden, on Thursday 2 April 2020 for the Annual General Meeting.

The income statements and the balance sheets for the Company and the group were approved and the Board of Directors and the CEO were discharged from liability for the financial year 2019.

The Meeting resolved to allocate the result in accordance with the proposal of the Board of Directors in the Annual Report.

In accordance with the proposal by the Nomination Committee, Dennis Stripe, Wilder Fulford, Christian Krüeger, Leif Ryd and Laura Shunk were re-elected as members of the Board of Directors, and Dennis Stripe was re-elected as Chairman of the Board of Directors.

In accordance with the proposal by the Nomination Committee, the Meeting resolved that total fees of SEK 1,100,000 are to be paid to the Board of Directors also going forward, of which SEK 400,000 to the Chairman of the Board of Directors, SEK 200,000 to each of Wilder Fulford, Christian Krüeger and Laura Shunk and SEK 100,000 to Leif Ryd. No fees are to be paid for committee work.

In accordance with the proposal by the Nomination Committee, the registered accounting firm KPMG AB was re-elected as the auditor of the Company, with the authorised public accountant Duane Swanson as the auditor in charge. The auditors fee shall be paid upon approval of their invoice.

The Meeting approved the Nomination Committees proposal on the nomination procedure and instruction for the Nomination Committee for the Annual General Meeting 2021.

The Meeting approved the Board of Directors proposal regarding guidelines for remuneration to senior executives.

In accordance with the proposal by the Board of Directors, the Meeting resolved on (i) adoption of an incentive programme, (ii) an issue of warrants of series 2020/2023(A), and (iii) an issue of warrants of series 2020/2023(B) and approval of transfers of warrants of series 2020/2023(B).

The incentive programme includes all employees in the Episurf group (22 persons).

No more than 220,000 warrants of series 2020/2023(A), no more than 3,080,000 employee stock options and no more than 2,619,939 performance options will be issued. The employee stock options and performance options are hedged by an issue of no more than 5,699,939 warrants of series 2020/2023(B) to the subsidiary Episurf Operations AB.

Each employee of the Episurf group (22 persons) shall be entitled to subscribe for up to 10,000 warrants of series 2020/2023(A).

The employee stock options shall be allocated in accordance with the following. Each employee of the Episurf group is proposed to be allotted, free of charge (i) 100,000 employee stock options (i.e. a total of 2,200,000 employee stock options) and (ii) four employee stock options for each warrant of series 2020/2023(A) subscribed for (i.e. a maximum of up to 880,000 employee stock options).

The performance options will be allotted to the participants free of charge in accordance with the following: (i) the CEO is allotted 756,942 performance options, (ii) the other members of the senior management (four persons) are allotted 1,416,647 performance options in total, of which no participant within this category may be allotted more than 385,989 performance options; and (iii) the other participants (nine persons) are allotted 446,350 performance options in total, of which no participant within this category may be allotted more than 66,814 performance options.

Each warrant of series 2020/2023(A) entitles its holder to subscribe for one share of series B in the Company during the period from and including 1 June 2023 until and including 31 May 2024 for a subscription price of SEK 1.73.

Provided that the participant is still employed by the Episurf group at the exercise of the employee stock options, each employee stock option entitles the employee to purchase one share of series B in the Company during the period from and including 1 June 2023 until and including 31 May 2024 for a price of SEK 1.73.

Provided that the participant is still employed by the Episurf group at the exercise of the performance options, each performance option entitles the employee to purchase one share of series B in the Company during the period from and including 1 June 2023 until and including 31 May 2024 for a price of SEK 1.73. Furthermore, the performance options are subject to certain performance targets for the financial year 2020, which determine to what extent the employees are entitled to keep and exercise the performance options.

The programme means that a maximum of 5,919,939 shares of series B may be issued, corresponding to a maximum dilution of approximately 3.1 per cent of the share capital and 3.0 per cent of the votes in the Company (provided full subscription in the ongoing fully guaranteed rights issue).

Finally, the Meeting resolved to authorise the Board of Directors to, during the period until the next Annual General Meeting, on one or more occasions, with or without deviation from the shareholders preferential rights, resolve on new issues of shares, convertibles and/or warrants in the Company. The number of shares issued by virtue of authorisation of the Meeting shall amount to not more than that is allowed within the, from time to time applicable, limits set forth in the Articles of Association of the Company when resolving on deviation from the shareholders preferential rights.

Fra 44minutter

https://www.redeye.se/live/IF-31-mars

1 Like

money in the bank

EPISURF

Episurfs företrädesemission fulltecknad sedan garanter tagit 56,6 procent (Finwire)

2020-04-07 15:36

Medicinteknikbolaget Episurf Medical tillförs 51 miljoner kronor före avdrag för emissionskostnader efter genomförd företrädesemission. Emissionen blev fulltecknad sedan garanterna tagit 56,6 procent av emissionen.

13 884 906 aktier, motsvarande cirka 40,7 procent av emissionen, tecknades med stöd av företrädesrätt (inklusitive. teckningsåtaganden). Därtill tecknades 918 363 aktier utan stöd av företrädesrätt, motsvarande cirka 2,7 procent av emissionen. 19 295 764 aktier, motsvarande cirka 56,6 procent av emissionen, tecknades av garanter.

“I en utmanande marknad har vi nu verkställt två transaktioner, varav en riktad emission och en företrädesemission. Jag är mycket glad över det stöd vi erhållit från både nya såväl som existerande ägare, och dessa emissioner stärker vår position inför framtiden. Jag vill också tacka våra rådgivare som arbetat med oss. Dessa transaktioner var viktiga för Episurf Medical. Vi ser fram emot att fortsätta att verkställa vår strategi, nu med en stärkt finansiering och ägarbild. Jag är också glad över det faktum att hela ledningsgruppen tecknat sig för sina andelar, precis som jag själv har gjort. Vi är mycket optimistiska om våra framtida möjligheter”, säger Pål Ryfors, vd Episurf Medical i ett pressmeddelande.

Lars Johansson
lars.johansson@finwire.se
Nyhetsbyrån Finwire

2 Likes

Det er jo spesielt hyggelig å se!

2 Likes

Også hyggelig at Pål er synlig på twitter:

4 Likes

Our updated, indicative Base Case is SEK 2.5 per share, effective immediately.

3 Likes

Analyse fra DnB ute nå, fva 1.6-4.3.

2 Likes

Aksjen er visst ikke populær nok for Tekbot så holmes får slå til

EPISURF MEDICAL AB
DNB Markets – Episurf Medical: Case getting stronger by the day (Cision)
2020-04-08 10:32
Yesterday, the company announced that the rights issue announced earlier this year has been completed. In our view, the company is clearly moving in the right direction with the financing being the last piece of the puzzle. In early 2020, it has released strong clinical data supporting the implant system, and now the financial situation is secured until 2022. In total, the company has raised cSEK140m before costs.

More and more clinical data has emerged during H1 2020. As we have pointed out before, clinical data is a prerequisite for a successful launch of a new implant system. Over the past months we have seen several press releases highlighting new data that supports the use of the Episealer system in patients with local cartilage injuries in the knee. We believe that the data seen in recent months points in the same direction, indicating that a patient-specific small implant is superior to both biological treatment and to total knee replacements.

The financial situation has improved making it possible for the company to execute on the strategy overall. With the rights issue in hand, the company has raised cSEK140m this year. This should be sufficient to take the company well into 2022 and also to secure the completion of the large IDE trial in the US, the EPIC-knee trial. In addition the company recently announced that it had received ethics committee approval for all European sites to be included in the IDE trial. Hence there will be patients recruited in Denmark, Germany and the UK in addition to the US patients in the trial.

The Talus implant approved in Europe in early 2020. As we have highlighted before, the product portfolio was recently enlarged by the approval in Europe of the Talus implant. This was positive but we also believe that the launch will be relatively slow as it is a complicated procedure.

Covid-19 will affect the operations. As for all other companies, the current pandemic seen across the world will affect Episurf Medical as well. In countries most affected by the pandemic we have seen the healthcare system postpone elective surgeries and prioritise to build out ICU capacity. Episurf’s procedures all fall in the category of elective procedures; hence we should expect a clear negative impact on the company’s sales.

Our fair value assessment for Episurf is SEK1.6–4.3.
Click here to view full report (https://www.dnb.no/seg-fundamental/fundamentalweb/GetReports.aspx?file=CMPSP_153834.pdf&Sid=1-7XT0MIJ)

3 Likes

2020 started very well for Episurf Medical. We experienced rapid growth, just as we had hoped for. Reported patient outcomes remained strong, and we completed the CE-marking process of our ankle implant. That said, late February, the operating environment changed dramatically as elective surgeries across Europe were postponed due to the Covid-19 situation. Of course, we fully support this line of action, and we are forever grateful to all our friends and customers in the healthcare system who are on the frontlines battling this virus. Even though the halt in elective surgeries negatively impacted about one-third of the quarter, we posted a 45% growth in our order-intake. says Pål Ryfors, CEO Episurf Medical.

First quarter 2020 compared to 2019, Group

  • Gross order intake amounted to SEK 1.6m (1.1), an increase by 45.5%. From late February, we noticed a negative impact from the outbreak of the Covid-19 as elective surgeries in Europe were temporarily halted

  • Order backlog amounted to SEK 1.0m (1.0)

  • Group net sales increased by 3.9% to SEK 1.5m (1.4)

  • 40.8% increase in orders for Episealer knee implants during the quarter with 69 (49) approved orders

  • Loss for the period amounted to SEK -17.9m (-14.6), the increased costs during the quarter are due to the groups work on the IDE study in the US, seasonal variations and business development projects

  • Earnings per share amounted to SEK -0.19 (-0.35)

Significant events during the first quarter

  • Episurf Medical announced a directed share issue and fully guaranteed rights issue of in total SEK 140m prior to transaction costs

  • Episurf Medical received CE mark for Episealer Talus and Talus Osteotomy Guide

  • Episurf Medical updated on AI-based production process

  • Episurf Medical reached milestone of 700 implants

  • Episurf Medical announced that the first surgery in Italy has been scheduled

  • Episealer was presented at a sports medicine meeting in Germany

  • Clinical data for Episealer were presented at orthopaedic congress in The United Kingdom

  • Important European patent approval received for Episurf Medical within 3D visualisation

  • Episurf Medical announced positive results from a clinical study with follow-up of the 30 first Swedish patients

  • Episurf Medical announced progress for European sites in the US clinical trial, the EPIC-Knee study

  • Episurf Medical announced positive results from the first comparative Episealer study

  • US patent approvals for Episurf Medical

  • Episealer Talus was registered for sale in Italy and Spain

Significant events after the first quarter

  • Episurf Medical conducted the rights issue and raised approximately SEK 51m prior to transaction costs

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical

2 Likes

Pål og Leif kjøper aksjer!

3 Likes

Og styreleder Stripe

EPISURF

Episurfs styrelseordförande ökar aktieinnehavet (Finwire)

2020-04-24 16:52

Medicinteknikbolaget Episurf Medicals styrelseordförande Dennis Stripe har den 24 april köpt 35 500 B-aktier i bolaget. Aktierna köptes till kursen 1,38 kronor per aktie, en affär på 49 000 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.

Henrik Öhlin
henrik.ohlin@finwire.se, 0703-21 06 99
Nyhetsbyrån Finwire

3 Likes
3 Likes

EPISURF

Episurfs styrelseordförande Dennis Stripe köper ytterligare aktier (Finwire)

2020-04-27 15:43

Medicinteknikbolaget Episurf Medicals styrelseordförande Dennis Stripe har den 27 april köpt ytterligare 62 000 B-aktier i bolaget. Aktierna köptes till kursen 1,38 kronor per aktie, en affär på 85 000 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.

Henrik Öhlin
henrik.ohlin@finwire.se, 0703-21 06 99
Nyhetsbyrån Finwire

3 Likes

EPISURF

Episurfs vd Pål Ryfors köper ytterligare aktier (Finwire)

2020-04-28 10:38

Medicinteknikbolaget Episurf Medicals vd Pål Ryfors har den 28 april köpt ytterligare 67 000 B-aktier i bolaget. Aktierna köptes till kursen 1,45 kronor per aktie, en affär på 97 000 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.

Henrik Öhlin
henrik.ohlin@finwire.se, 0703-21 06 99
Nyhetsbyrån Finwire

2 Likes

Styreleder kjøper aksjer for 0,0001 milliarder kroner :wink:

EPISURF

Episurfs ordförande har köpt aktier för 0,1 miljoner kronor (Finwire)

2020-04-29 10:26

Dennis Stripe har den 28 april köpt 67 000 aktier i Episurf där han är styrelseordförande. Aktierna köptes till kursen 1,50 kronor per aktie. Köpesumman uppgår till 100 359 kronor.

Det framgår av Finansinspektionens insynsregister.

Stefan Linnér
stefan.linner@finwire.se
Nyhetsbyrån Finwire

3 Likes

Dette begynner å se lovende ut, SMA55 uker i ferd med å brytes + kursen er over siste emisjon allerede.

3 Likes

EPISURF

Episurfs styrelseordförande Dennis Stripe fortsätter att öka på aktieinnehavet (Finwire)

2020-05-04 15:20

Medicinteknikbolaget Episurf Medicals styrelseordförande Dennis Stripe fortsätter att öka sitt aktieinnehav i bolaget. Det senaste köpet skedde den 4 maj då 62 250 aktier köptes till kursen 1,47 kronor per aktie, en affär på 92 000 kronor. Affären gjordes på Nasdaq Stockholm. Det framgår av Finansinspektionens insynsregister.

Henrik Öhlin
henrik.ohlin@finwire.se, 0703-21 06 99
Nyhetsbyrån Finwire

4 Likes

Klarer snart ikke vente lengre, vurderer sterkt å følge opp kjøpene til Stripe.

3 Likes

Innsiderene i episurf er episke

Lenge siden jeg har sett på denne. Er det noen som vet hvordan kassabeholdningen ser ut? Lenge siden siste emi?